FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a fo...
SciSparc Ltd. announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of...
Tiger BioSciences highlights a series of major clinical and scientific achievements resulting from the company's expanded investment in evidence‑based ...
Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-...
NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Bo...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...
Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its markete...
Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, ...
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifida...
T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...
Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two...
The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimula...
© 2026 Biopharma Boardroom. All Rights Reserved.
